Gsa Capital Partners LLP Arrowhead Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

$1.32 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$27.21 - $39.48 $127,587 - $185,121	-4,689 Reduced 29.89%	10,999 $314,000
Q4 2023 Feb 16, 2024	SELL	$21.2 - $31.03 $674,986 - $987,964	-31,839 Reduced 66.99%	15,688 $480,000
Q3 2023 Nov 15, 2023	BUY	$26.2 - $36.08 $1.25 Million - $1.71 Million	47,527 New	47,527 $1.28 Million
Q1 2023 May 12, 2023	BUY	$23.68 - $38.51 $877,888 - $1.43 Million	37,073 New	37,073 $941,000
Q3 2022 Nov 14, 2022	SELL	$29.63 - $48.31 $556,866 - $907,938	-18,794 Reduced 62.15%	11,447 $378,000
Q2 2022 Aug 09, 2022	BUY	$27.79 - $50.61 $525,092 - $956,275	18,895 Added 166.53%	30,241 $1.07 Million
Q1 2022 May 11, 2022	BUY	$39.62 - $69.97 $449,528 - $793,879	11,346 New	11,346 $522,000
Q2 2020 Aug 11, 2020	SELL	$26.12 - $43.27 $196,187 - $325,000	-7,511 Closed	0 $0
Q1 2020 May 12, 2020	BUY	$20.56 - $63.12 $63,962 - $196,366	3,111 Added 70.7%	7,511 $216,000
Q4 2019 Feb 12, 2020	SELL	$28.14 - $73.01 $146,328 - $379,652	-5,200 Reduced 54.17%	4,400 $279,000
Q3 2019 Nov 12, 2019	SELL	$26.26 - $34.86 $688,012 - $913,332	-26,200 Reduced 73.18%	9,600 $271,000
Q2 2019 Aug 06, 2019	SELL	$17.43 - $28.82 $589,360 - $974,490	-33,813 Reduced 48.57%	35,800 $949,000
Q1 2019 May 15, 2019	BUY	$12.05 - $20.18 $595,221 - $996,811	49,396 Added 244.33%	69,613 $1.28 Million
Q4 2018 Feb 12, 2019	BUY	$10.74 - $19.7 $217,130 - $398,274	20,217 New	20,217 $251,000
Q2 2018 Aug 09, 2018	SELL	$6.37 - $14.02 $853,382 - $1.88 Million	-133,969 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$3.72 - $7.64 $498,364 - $1.02 Million	133,969 New	133,969 $966,000

Others Institutions Holding ARWR

# of Institutions

294

Shares Held

90.8M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.08B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account